Ronnie Shapira-Frommer Selected Research

Ronnie Shapira-Frommer Research Topics

Disease

30	Neoplasms (Cancer) 01/2024 - 02/2008
27	Melanoma (Melanoma, Malignant) 06/2023 - 05/2009
21	Ovarian Neoplasms (Ovarian Cancer) 11/2023 - 04/2012
9	Fatigue 11/2022 - 04/2012
8	Disease Progression 10/2023 - 10/2013
6	Uterine Cervical Neoplasms (Cancer of the Cervix) 12/2023 - 10/2019
6	Nausea 11/2022 - 04/2012
5	Carcinoma (Carcinomatosis) 03/2023 - 08/2017
5	Neoplasm Metastasis (Metastasis) 01/2023 - 06/2014
5	Anemia 11/2022 - 04/2012
5	Vomiting 11/2019 - 04/2012
4	Pneumonia (Pneumonitis) 12/2023 - 08/2015
4	Neutropenia 11/2022 - 08/2015
4	Asthenia 01/2021 - 08/2017
4	Breast Neoplasms (Breast Cancer) 01/2019 - 02/2008
3	Colitis 12/2018 - 08/2015
2	Adenocarcinoma 12/2023 - 12/2023
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2023 - 01/2022
2	Endometrial Neoplasms (Endometrial Cancer) 01/2023 - 01/2022
2	Mesothelioma 01/2021 - 10/2020
1	Adenosquamous Carcinoma 12/2023
1	Pulmonary Embolism 12/2023
1	Urinary Tract Infections (Urinary Tract Infection) 12/2023
1	Sepsis (Septicemia) 12/2023
1	Ameloblastoma 11/2023
1	Thrombocytopenia (Thrombopenia) 11/2022
1	Uveal melanoma 01/2022
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Fever (Fevers) 01/2021
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2020
1	Diarrhea 12/2018
1	Atrophy 12/2018
1	Steatorrhea 12/2018
1	Hypophysitis 03/2018
1	Exanthema (Rash) 03/2018
1	Hepatitis 03/2018
1	Hyponatremia 08/2015
1	Hypopituitarism (Sheehan's Syndrome) 08/2015
1	Myalgia 08/2015
1	Body Weight (Weight, Body) 06/2015
1	Pancreatic Diseases (Pancreatic Disease) 01/2015
1	Prostatic Neoplasms (Prostate Cancer) 01/2015

Drug/Important Bio-Agent (IBA)

21	PlatinumIBA 12/2023 - 04/2012
15	Poly(ADP-ribose) Polymerase InhibitorsIBA 03/2023 - 10/2013
14	pembrolizumabIBA 12/2023 - 06/2015
12	olaparibIBA 11/2021 - 04/2012
7	Biomarkers (Surrogate Marker)IBA 12/2023 - 09/2013
7	rucaparibIBA 03/2023 - 08/2017
6	IpilimumabIBA 01/2022 - 09/2012
5	Bevacizumab (Avastin)FDA Link 12/2023 - 11/2021
5	Immune Checkpoint InhibitorsIBA 12/2023 - 06/2015
4	Paclitaxel (Taxol)FDA LinkGeneric 10/2023 - 01/2021
4	SteroidsIBA 06/2023 - 03/2018
4	Interleukin-2 (IL2)IBA 11/2015 - 05/2009
3	lenvatinibIBA 01/2023 - 01/2022
3	NivolumabIBA 01/2022 - 03/2018
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2021 - 02/2016
3	Hemoglobins (Hemoglobin)IBA 01/2021 - 11/2017
2	Carboplatin (JM8)FDA LinkGeneric 12/2023 - 01/2023
2	Cisplatin (Platino)FDA LinkGeneric 12/2023 - 01/2023
2	Monoclonal AntibodiesIBA 01/2023 - 03/2018
2	B7-H1 AntigenIBA 11/2021 - 10/2019
2	Alanine Transaminase (SGPT)IBA 01/2021 - 08/2017
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 08/2017
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 08/2015
1	LigandsIBA 12/2023
1	durvalumabIBA 12/2023
1	Indicators and Reagents (Reagents)IBA 03/2023
1	Small Interfering RNA (siRNA)IBA 01/2023
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2023
1	prexasertibIBA 11/2022
1	DNA (Deoxyribonucleic Acid)IBA 11/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021
1	Chimeric Antigen ReceptorsIBA 01/2021
1	CreatinineIBA 01/2021
1	fludarabineIBA 01/2021
1	Messenger RNA (mRNA)IBA 09/2019
1	RNA (Ribonucleic Acid)IBA 09/2019
1	niraparibIBA 01/2019
1	EnzymesIBA 12/2018
1	Methotrexate (Mexate)FDA LinkGeneric 03/2018
1	SCH772984IBA 01/2018
1	MK-8353IBA 01/2018
1	Poly Adenosine Diphosphate RiboseIBA 06/2016
1	Capsules (Microcapsules)IBA 02/2016
1	Gemcitabine FDA Link 01/2015
1	MicroRNAs (MicroRNA)IBA 09/2013
1	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2013
1	VemurafenibIBA 09/2012

Therapy/Procedure

28	Therapeutics 01/2024 - 03/2011
20	Drug Therapy (Chemotherapy) 12/2023 - 02/2008
15	Immunotherapy 06/2023 - 09/2013
7	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2023 - 05/2009
2	Chemoradiotherapy 12/2023 - 12/2023
2	Salvage Therapy 01/2020 - 11/2015
1	Palliative Care (Palliative Therapy) 01/2022
1	Radiotherapy 01/2022
1	Fecal Microbiota Transplantation 01/2021
1	Cytoreduction Surgical Procedures 10/2013